PriceTargets.com logo

Elicio Therapeutics - ELTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 727.36%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.81 As of 10/8/2026 04:56 PM ET
▼ -0.037 (-2.00%)

This chart shows the closing price for ELTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Elicio Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELTX

Analyst Price Target is $15.00
▲ +727.36% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Elicio Therapeutics in the last 3 months. The average price target is $15.00, with a high forecast of $23.00 and a low forecast of $8.00. The average price target represents a 727.36% upside from the last price of $1.81.

This chart shows the closing price for ELTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 investment analysts is to moderate buy stock in Elicio Therapeutics. This rating has held steady since February 2026, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/15/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/14/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/12/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/10/2026
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/10/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/9/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/7/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/7/2026

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/24/2026B. Riley FinancialLower TargetBuy ➝ Buy$8.00
8/18/2026HC WainwrightReiterated RatingBuy ➝ Buy
7/29/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
7/14/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
6/18/2026LADENBURG THALM/SH SHInitiated CoverageBuy$12.00
6/16/2026JonesTradingDowngradeBuy ➝ Hold
6/15/2026Rodman & RenshawReiterated RatingBuy ➝ Buy
6/15/2026HC WainwrightBoost TargetBuy ➝ Buy$17.00 ➝ $23.00
6/10/2026B. Riley FinancialInitiated CoverageBuy$27.00
5/28/2026HC WainwrightReiterated RatingBuy ➝ Buy$17.00
4/24/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
4/15/2026LADENBURG THALM/SH SHInitiated CoverageBuy$20.00
3/13/2026HC WainwrightBoost TargetBuy ➝ Buy$13.00 ➝ $17.00
3/10/2026Rodman & RenshawUpgradeStrong-Buy
3/9/2026Rodman & RenshawInitiated CoverageBuy$17.00
12/29/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/15/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/24/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/11/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/5/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/28/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/14/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
7/17/2025HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $13.00
4/2/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
8/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
6/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00
5/1/2024HC WainwrightLower TargetBuy ➝ Buy$11.00 ➝ $10.00
4/1/2024OppenheimerReiterated RatingMarket Perform ➝ Market Perform
1/17/2024HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $11.00
10/26/2023HC WainwrightReiterated RatingBuy$12.00
(Data available from 10/8/2021 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/12/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/11/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/11/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/10/2026
  • 1 very positive mentions
  • 17 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
7/10/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/9/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/8/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/8/2026

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Elicio Therapeutics logo
Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.
Read More

Today's Range

Now: $1.81
Low: $1.74
High: $1.85

50 Day Range

MA: $2.49
Low: $1.77
High: $3.19

52 Week Range

Now: $1.81
Low: $1.71
High: $16.00

Volume

130,599 shs

Average Volume

677,959 shs

Market Capitalization

$47.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Elicio Therapeutics?

The following Wall Street analysts have issued research reports on Elicio Therapeutics in the last twelve months: B. Riley Financial, Inc., HC Wainwright, JonesTrading, LADENBURG THALM/SH SH, Rodman & Renshaw, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for ELTX.

What is the current price target for Elicio Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Elicio Therapeutics in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 758.6%. HC Wainwright has the highest price target set, predicting ELTX will reach $23.00 in the next twelve months. B. Riley Financial, Inc. has the lowest price target set, forecasting a price of $8.00 for Elicio Therapeutics in the next year.
View the latest price targets for ELTX.

What is the current consensus analyst rating for Elicio Therapeutics?

Elicio Therapeutics currently has 1 sell rating, 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ELTX.

What other companies compete with Elicio Therapeutics?

Other companies that are similar to Elicio Therapeutics include Cue Biopharma, Nkarta, Compass Therapeutics, Anavex Life Sciences and Coherus Oncology. Learn More about companies similar to Elicio Therapeutics.

How do I contact Elicio Therapeutics' investor relations team?

Elicio Therapeutics' physical mailing address is 51 Charles Lindbergh Boulevard, Uniondale NY, 11553. The company's listed phone number is 415-655-4899 and its investor relations email address is [email protected]. The official website for Elicio Therapeutics is www.angion.com. Learn More about contacing Elicio Therapeutics investor relations.